The 30 references in paper E. Shatokhina A., L. Kruglova S., Е. Шатохина А., Л. Круглова С. (2019) “Акнеподобная сыпь - кожная токсическая реакция на применение ингибиторов EGFR // Acneiform rash — skin toxic reaction to the use of EGFR inhibitors” / spz:neicon:ogsh:y:2018:i:4:p:48-55

1
Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol
(check this in PDF content)
2
05;23(22):5235–46. DOI: 10.1200/JCO.2005.00.6916. PMID: 16051966. 2. Joshi S. S., Ortiz S., Witherspoon J. N. et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116(16):3916–23. DOI: 10.1002/cncr.25090. PMID: 20564072.
(check this in PDF content)
3
Boone S. L., Rademaker A., Liu D. et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72(3–4):152–9. DOI: 10.1159/000112795. PMID: 18160805.
(check this in PDF content)
4
Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16(9):1425–33. DOI: 10.1093/annonc/mdi279. PMID: 16012181.
(check this in PDF content)
5
Segaert S., Chiritescu G., Lemmens L. et al. Skin toxicities of targeted therapies. Eur J Cancer 2009;45(Suppl 1):295–308. DOI: 10.1016/S0959-8049(09)70044-9. PMID: 19775626.
(check this in PDF content)
6
Perez-Soler R., Delord J. P., Halpern A. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10(5):345–56. DOI: 10.1634/ theoncologist.10-5-345. PMID: 15851793.
(check this in PDF content)
7
Robert C., Soria J. C., Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6(7):491–500. DOI: 10.1016/S14702045(05)70243-6. PMID: 15992698.
(check this in PDF content)
8
Burtness B., Anadkat M., Basti S. et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7(Suppl 1):S5–21. PMID: 19470276.
(check this in PDF content)
9
Jacot W., Bessis D., Jorda E. et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151(1):238–41. DOI: 10.1111/j.1365-2133.2004.06026.x. PMID: 15270903.
(check this in PDF content)
10
Galimont-Collen A. F., Vos L. E., Lavrijsen A. P. et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor(EGFR) inhibitors. Eur J Cancer 2007;43(5):845–51. DOI: 10.1016/j.ejca.2006.11.016. PMID: 17289377.
(check this in PDF content)
11
Agero A. L., Dusza S. W., BenvenutoAndrade C. et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55(4):657–70. DOI: 10.1016/j. jaad. 2005.10.010. PMID: 17010747.
(check this in PDF content)
12
Roé E., Garcia Muret M. P., Marcuello E. et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006;55(3):429–37.DOI: 10.1016/j.jaad. 2006.04.062. PMID: 16908348.
(check this in PDF content)
13
Wacker B., Nagrani T., Weinberg J. et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13(13):3913–21. DOI: 10.1158/1078-0432.CCR-06-2610. PMID: 17606725.
(check this in PDF content)
14
Fernández-Torres R., Martinez Gomez W., Cuevas Santos J. et al. Rosaceiform eruption induced by cetuximab. Eur J Dermatol 2010;20(3):392–3. DOI: 10.1684/ejd. 2010.0900. PMID: 20172848.
(check this in PDF content)
15
Wolf M., Swaisland H., Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004;10(14):4607–13. DOI: 10.1158/1078-0432.CCR-04-0058. PMID: 15269131.
(check this in PDF content)
16
Peeters M., Siena S., Van Cutsem E. et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115(7):1544–54. DOI: 10.1002/cncr.24088. PMID: 19189371.
(check this in PDF content)
17
Cutsem E., Tejpar S., Vanbeckevoort D. et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012;30(23):2861–8. DOI: 10.1200/JCO.2011.40.9243. PMID: 22753904.
(check this in PDF content)
18
Senderowicz A. M., Johnson J. R., Sridhara R. et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 2007;21(14):1696–706. PMID: 18247017. с другими комбинациями дало применение крема, содержащего 0,1 % бетаметазона валерат и 20 % фузидовую кислоту. Оно привело к наиболее выраженному и быстрому регрессу клинической симптоматики и значительно повысило качество жизни больных. Менее эффективными оказались схемы лечения, которые включали помимо системной терапии доксициклином лечение гелем, содержащим 1 % метронидазол, и крем, содержащий 0,1 % такролимус, причем последняя схема имела наименьшую эффективность. В связи с недостаточным ответом на терапию через 1 мес лечения пациенты были переведен
(check this in PDF content)
19
Shepherd F. A., Rodrigues Pereira J., Ciuleanu T. et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123–32. DOI: 10.1056/NEJMoa050753. PMID: 16014882.
(check this in PDF content)
20
Perez-Soler R., Chachoua A., Hammond L. A. et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238–47. DOI: 10.1200/ JCO.2004.11.057. PMID: 15310767.
(check this in PDF content)
21
Ouwerkerk J, Boers-Doets C Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010;14(4):337–49. DOI: 10.1016/j. ejon.2010.03.004. PMID: 20580896.
(check this in PDF content)
22
Bernier J., Bonner J., Vermorken J. B. et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142–9. DOI: 10.1093/annonc/ mdm400. PMID: 17785763.
(check this in PDF content)
23
Jatoi A., Green E. M., Rowland K. M. Jr et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009;77(2):120–3. DOI: 10.1159/ 000229751. PMID: 19622902.
(check this in PDF content)
24
Cunningham D., Humblet Y., Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337–45. DOI: 10.1056/NEJMoa033025. PMID: 15269313.
(check this in PDF content)
25
Togashi Y., Masago K., Fujita S. et al. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with nonsmall cell lung cancer. Lung Cancer 2011;74(1):98–102. DOI: 10.1016/j. lungcan.2011.01.022. PMID: 21377230.
(check this in PDF content)
26
Grenader T., Gipps M., Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9(1):59–60. DOI: 10.3816/CLC.2008.n.010. PMID: 18282360.
(check this in PDF content)
27
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Available at: https://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf.
(check this in PDF content)
28
Королева И. А., Болотина Л. В., Гладков О. А. и др. Практические рекомендации по лекарственному лечению дерматологических осложнений противоопухолевой лекарственной терапии. Злокачественные опухоли 2017;7(3-S2): 514–23. [Koroleva I. A., Bolotina L. V., Gladkov O. A. et al. Practical recommen dations for drug treatment of dermato logical complications of anticancer drug therapy. Zlokachestvennye opuholi = Malignant tumors 2017;7(3-S2):514–23. (In Russ.)].
(check this in PDF content)
29
Кочергин Н.А., Самгин М.А., Монахов С.А., Игнатьев Д. Дерматологический индекс акне. Эстетическая медицина 2004;3(1):62–5. [Kochergin N.A., Samgin M.A., Monakhov S.A., Ignat’ev D. Acne Dermatology Index. Esteticheskaya meditsina = Aesthetic Medicine 2004;3(1):62–5. (In Russ.)].
(check this in PDF content)
30
Dermatology Quality of Life Index (DLQI). Available at: http://www.cardiff.ac.uk/dermatology/ quality-of-life/dermatology-quality-oflife-index-dlqi/
(check this in PDF content)